Business Wire

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial ...

Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. Platform is based on a proprietary biological discovery called HYFT™ patterns, signature sequences in DNA, RNA, and ...
Benzinga.com

EXCLUSIVE: Antibody-Discovery Platform Provider ImmunoPrecise's Subsidiary Highlights Approach to Biological Sequence Retrieval

The paper introduces HYFT patterns as unique signature sequences, akin to biological fingerprints, found in amino acids, DNA, and RNA. These patterns serve as a tool to tokenize all biological data ...
Business Wire

IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant

DIEPENBEEK, Belgium--(BUSINESS WIRE)--Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA’s subsidiary Biostrand, a Belgian end-to ...
Financial Post

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial ...

New Platform Integrates Sequence Data and Information from Entire Biosphere Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. Platform is based on a proprietary ...
The Globe and Mail

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial ...

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to acquire, through ...